Clinical Trials Browser

Phase 2 × Lymphoma × Sulfasalazine × Clear all

NCT06557330 2025-01-06

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Phase 2 Not yet recruiting

Lymphoma